167 related articles for article (PubMed ID: 22278362)
41. Altered skeletal muscle microtubule-mitochondrial VDAC2 binding is related to bioenergetic impairments after paclitaxel but not vinblastine chemotherapies.
Ramos SV; Hughes MC; Perry CGR
Am J Physiol Cell Physiol; 2019 Mar; 316(3):C449-C455. PubMed ID: 30624982
[TBL] [Abstract][Full Text] [Related]
42. Nakiterpiosin targets tubulin and triggers mitotic catastrophe in human cancer cells.
Wei JH; Seemann J
Mol Cancer Ther; 2010 Dec; 9(12):3375-85. PubMed ID: 21139045
[TBL] [Abstract][Full Text] [Related]
43. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells.
Alli E; Yang JM; Ford JM; Hait WN
Mol Pharmacol; 2007 May; 71(5):1233-40. PubMed ID: 17272681
[TBL] [Abstract][Full Text] [Related]
44. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
[TBL] [Abstract][Full Text] [Related]
45. The Mammalian Septin Interactome.
Neubauer K; Zieger B
Front Cell Dev Biol; 2017; 5():3. PubMed ID: 28224124
[TBL] [Abstract][Full Text] [Related]
46. Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine.
Rathinasamy K; Jindal B; Asthana J; Singh P; Balaji PV; Panda D
BMC Cancer; 2010 May; 10():213. PubMed ID: 20482847
[TBL] [Abstract][Full Text] [Related]
47. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
[No Abstract] [Full Text] [Related]
48. Targeted knockdown of SEPT9_v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway.
Amir S; Golan M; Mabjeesh NJ
Mol Cancer Res; 2010 May; 8(5):643-52. PubMed ID: 20407014
[TBL] [Abstract][Full Text] [Related]
49. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
50. Multimodality expression profiling shows SEPT9 to be overexpressed in a wide range of human tumours.
Scott M; Hyland PL; McGregor G; Hillan KJ; Russell SE; Hall PA
Oncogene; 2005 Jul; 24(29):4688-700. PubMed ID: 15782116
[TBL] [Abstract][Full Text] [Related]
51. Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine.
Hari M; Wang Y; Veeraraghavan S; Cabral F
Mol Cancer Ther; 2003 Jul; 2(7):597-605. PubMed ID: 12883031
[TBL] [Abstract][Full Text] [Related]
52. Septin 9 isoform 1 (SEPT9_i1) specifically interacts with importin-α7 to drive hypoxia-inducible factor (HIF)-1α nuclear translocation.
Tazat K; Schindler S; Depping R; Mabjeesh NJ
Cytoskeleton (Hoboken); 2019 Jan; 76(1):123-130. PubMed ID: 29742803
[TBL] [Abstract][Full Text] [Related]
53. Amino acid substitutions at proline 220 of beta-tubulin confer resistance to paclitaxel and colcemid.
Yin S; Cabral F; Veeraraghavan S
Mol Cancer Ther; 2007 Oct; 6(10):2798-806. PubMed ID: 17938271
[TBL] [Abstract][Full Text] [Related]
54. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators.
Wilson L; Panda D; Jordan MA
Cell Struct Funct; 1999 Oct; 24(5):329-35. PubMed ID: 15216890
[TBL] [Abstract][Full Text] [Related]
55. Spatial effects - site-specific regulation of actin and microtubule organization by septin GTPases.
Spiliotis ET
J Cell Sci; 2018 Jan; 131(1):. PubMed ID: 29326311
[TBL] [Abstract][Full Text] [Related]
56. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.
Wang Y; O'Brate A; Zhou W; Giannakakou P
Cell Cycle; 2005 Dec; 4(12):1847-53. PubMed ID: 16294009
[TBL] [Abstract][Full Text] [Related]
57. An antitubulin agent BCFMT inhibits proliferation of cancer cells and induces cell death by inhibiting microtubule dynamics.
Rai A; Surolia A; Panda D
PLoS One; 2012; 7(8):e44311. PubMed ID: 22952952
[TBL] [Abstract][Full Text] [Related]
58. Septin roles in tumorigenesis.
Connolly D; Abdesselam I; Verdier-Pinard P; Montagna C
Biol Chem; 2011 Aug; 392(8-9):725-38. PubMed ID: 21740328
[TBL] [Abstract][Full Text] [Related]
59. Discovery of Inhibitors of Membrane Traffic from a Panel of Clinically Effective Anticancer Drugs.
Kamata H; Sadahiro S; Yamori T
Biol Pharm Bull; 2019 May; 42(5):814-818. PubMed ID: 30787205
[TBL] [Abstract][Full Text] [Related]
60. Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity.
Sun X; Li D; Yang Y; Ren Y; Li J; Wang Z; Dong B; Liu M; Zhou J
J Pathol; 2012 Mar; 226(4):666-73. PubMed ID: 21989536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
